Lijuan Deng

ORCID: 0009-0006-0469-1437
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Membrane Separation Technologies
  • Lymphoma Diagnosis and Treatment
  • Membrane-based Ion Separation Techniques
  • Wastewater Treatment and Nitrogen Removal
  • CAR-T cell therapy research
  • CNS Lymphoma Diagnosis and Treatment
  • Microbial Fuel Cells and Bioremediation
  • Recycling and Waste Management Techniques
  • Chronic Lymphocytic Leukemia Research
  • Pharmaceutical and Antibiotic Environmental Impacts
  • Solar-Powered Water Purification Methods
  • Viral-associated cancers and disorders
  • Wound Healing and Treatments
  • Monoclonal and Polyclonal Antibodies Research
  • Crystallization and Solubility Studies
  • Quantum Dots Synthesis And Properties
  • Extraction and Separation Processes
  • Lung Cancer Treatments and Mutations
  • Pressure Ulcer Prevention and Management
  • Microbial Community Ecology and Physiology
  • Diabetic Foot Ulcer Assessment and Management
  • Advanced Chemical Physics Studies
  • Chalcogenide Semiconductor Thin Films
  • SARS-CoV-2 and COVID-19 Research
  • Integrated Circuits and Semiconductor Failure Analysis

Peking University
2014-2025

Peking University Cancer Hospital
2014-2025

Sichuan University
2010-2025

West China Hospital of Sichuan University
2025

Kunming University
2025

South China University of Technology
2024

University of Technology Sydney
2015-2024

Beijing University of Chinese Medicine
2022-2024

Shanghai Institute of Materia Medica
2024

Chinese Academy of Sciences
2024

The paradoxical coexistence of spontaneous tumor antigen-specific immune response with progressive disease in cancer patients need to dissect the molecular pathways involved tumor-induced T-cell dysfunction or exhaustion. Programmed cell death 1 (PD-1) has been identified as a marker exhausted T cells chronic states, and blockade PD-1-PD-L1 interactions shown partially restore function. We have found that immunoglobulin mucin (Tim) 3 is expressed on CD8 + tumor-infiltrating lymphocytes...

10.1097/cji.0000000000000122 article EN Journal of Immunotherapy 2016-04-19

Abstract Background The treatment outcomes and prognosis of lymphoma are affected by various factors such as hospital types. This study was to describe the temporal trend in survival an academic center China. Methods A total 3840 consecutive patients with diagnosed between 1996 2015 were reviewed. Eighty excluded, finally, 3760 analyzed this study. cohort divided into four groups according calendar periods at diagnosis: 1996‐2000, 2001‐2005, 2006‐2010, 2010‐2015. overall (OS) rates among...

10.1002/cam4.3037 article EN cc-by Cancer Medicine 2020-04-12

The MICA (MHC class I chain-related molecule A) is a ligand for the activating immunoreceptor NKG2D (natural killer group 2, member D). recognizes expressing at cell surface elimination. Although overexpressed in many kinds of tumours, tumour cells can cleverly escape immunosurveillance. One underlying mechanism immunoescape tumour-derived shedding. In this study, we report that osteosarcoma-derived results from proteolytic cleavage α3 ectodomain. sMICA (soluble MICA) might be released early...

10.1042/cbi20100431 article EN Cell Biology International 2011-02-22
Coming Soon ...